CheckMate 214 Updates: OS, PFS and response data for nivolumab plus ipilimumab versus sunitinib in advanced RCC through >4 years of follow-up
In the past decade, various targeted therapies have demonstrated improvement in outcomes for patients with advanced renal cell carcinoma (RCC).1 However, most patients on targeted therapy eventually...